News

Greenwich Biosciences Inc., is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.

Investor Inquiries

Stephen Schultz
Vice President, Investor Relations
Tel: +1 917.280.2424 Direct
Email
Fax: 760.795.2219

Media Inquiries

Stephen Schultz
Vice President, Investor Relations
Tel: +1 917.280.2424 Direct
Email
Fax: 760.795.2219

May 16, 2018
Greenwich Biosciences’ Spotlight highlights various aspects of our scientific research and cannabinoid clinical development program. We bring forward the voices of our dedicated employees and members of the medical, caregiver and advocacy community who make an invaluable contribution to our efforts.
Apr 25, 2018
In late 2017, when the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for an investigational cannabidiol (CBD) for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) and Dravet syndrome, it marked a significant milestone for Greenwich Biosciences.